Chemomab Therapeutics Ltd. SEC filings CMMB

Chemomab Therapeutics Ltd. has 366 filings in SEC EDGAR's recent list, going back to Nov 7, 2011. Its latest annual report, Form 20-F, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 11, 2023, covering the quarter ended Mar 31, 2023. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.

Form Description Filed Period
DEFM14A Filing Oct 30, 2026 —
DEFA14A Additional proxy material May 31, 2022 —
DEF 14A Proxy statement Apr 28, 2022 Apr 28, 2022
DEF 14A Proxy statement Jan 5, 2022 Jan 5, 2022
PRE 14A Preliminary proxy statement Dec 23, 2021 Dec 23, 2021
DEF 14A Proxy statement Sep 17, 2021 Sep 17, 2021
PRE 14A Preliminary proxy statement Sep 3, 2021 Sep 3, 2021
DEF 14A Proxy statement Jun 14, 2021 Jun 14, 2021
PRE 14A Preliminary proxy statement Jun 1, 2021 Jun 1, 2021
DEFA14A Additional proxy material Dec 15, 2020 —
DEFA14A Additional proxy material Apr 17, 2020 —
DEF 14A Proxy statement Apr 6, 2020 Apr 23, 2020
PRE 14A Preliminary proxy statement Mar 30, 2020 Apr 23, 2020

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CMMB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Israel
Headquarters
Tel Aviv
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1534248
Former names
Anchiano Therapeutics Ltd. (until Mar 17, 2021); BioCancell Ltd. (until Nov 3, 2015)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.